News - Norgine, Lyxumia


Current filters:


Popular Filters

1 to 25 of 28 results

Norgine and Kissei’s Savene approved in Japan


Independent Dutch firm Norgine and its Japanese partner Kissei Pharmaceutical received approval from…

Asia-PacificKissei PharmaceuticalNorgineOncologyPharmaceuticalRegulationSavene

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan

Zealand Pharma achieves milestone in Sanofi collaboration on LixiLan


Denmark’s Zealand Pharma says it has achieved a milestone under its collaboration with French drug…

DiabetesFinancialLixiLanLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study

Sanofi’s Lyxumia meets primary endpoint in Ph IIIb diabetes study


Results of a 24-week Phase IIIb clinical study showed that French drug major Sanofi’s diabetes drug…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Lyxumia plus basal insulin lowers blood sugar, latest data show

Lyxumia plus basal insulin lowers blood sugar, latest data show


Sanofi has announced new GetGoal-L sub-analysis results showing that reductions in HbA1c with Lyxumia…

DiabetesLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi temporarily pulls lixisenatide NDA in USA


French drug major Sanofi (Euronext: SAN) this morning (September 12) announced its decision to withdraw…

DiabeteslixisenatideLyxumiaNorth AmericaPharmaceuticalRegulationSanofiZealand Pharma

Study finds Norgine's Dantrium reduces fatal anesthetic reactions


A new epidemiologic study has found that Dantrium (dantrolene sodium) is effective in reducing fatal…

NorgineNorth AmericaPharmaceuticalResearch

Sanofi's once-daily diabetes drug Lyxumia approved in Europe


French drug major Sanofi (Euronext: SAN) this morning announced that the European Commission has granted…


Alfa Wassermann and Norgine's Targaxan gets first European launch, in UK


Following recent European Union approval (The Pharma Letter December 9, 2012), Netherlands-based Norgine…

Alfa WassermannEuropeMarkets & MarketingNephrology and HepatologyNorginePharmaceuticalTargaxanXifaxan

Norgine and SpePharm set up JV to commercialize portfolio of drugs


Independent Dutch firm Norgine BV and fellow Amsterdam-based SpePharm Holding BV have concluded a broad…

Markets & MarketingMergers & AcquisitionsNorginePharmaceuticalSpePharma

Alfa Wassermann and Norgine get EU approval for Xifaxan


Italy-based Alfa Wassermann and Netherlands-headquartered Norgine say they have received European Marketing…

Alfa WassermannAntibiotics and Infectious diseasesEuropeNorginePharmaceuticalRegulationXifaxan

Zealand Pharma valuation hinged on Lyxi/Lanti "fixflex"


The recent European Medicine Agency advisory committee, CHMP, positive opinion for French drug major…

BiotechnologyDiabetesFinancialLantusLyxumiaNovo NordiskRegulationResearchSanofiTresibaVictozaZealand Pharma

Positive CHMP recommendations for Sanofi and Novartis, but not for Celgene


There was a batch of good news for two pharma companies and a negative opinion for one last Friday coming…


Sanofi files for Japanese approval of diabetes drug Lyxumia


French drug major Sanofi (Euronext: SAN), has submitted a marketing authorization application for lixisenatide…

Asia-PacificDiabeteslixisenatideLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Highlights of American Diabetes Association meeting


The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Tranzyme and Norgine's ulimorelin fails to meet endpoints


USA-based Tranzyme Pharma (Nasdaq: TZYN) and independent Dutch drugmaker Norgine have announced disappointing…


Tranzyme and Norgine bowel cancer drug fails in Ph III


USA-based Tranzyme Pharma (Nasdaq: TZYM) and independent drugmaker Norgine of the Netherlands yesterday…


$20 million lixisenatide milestone for Zealand Pharma


Danish peptide drug discovery firm Zealand Pharma (Nasdaq OMX Copenhagen: ZEAL) says it will receive…

DiabetesFinanciallixisenatideLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Sanofi files for EU approval of Lyxumia, a type-2 diabetes agent partnered with Zealand Pharma


Danish drug discovery firm Zealand Pharma (Nasdaq OMX: ZEAL.CO), says that its partner, French drug major…

DiabetesFinancialLyxumiaPharmaceuticalRegulationSanofiZealand Pharma

Sanofi presents positive results with Lyxumia and Lantus in type 2 diabetes at EASD meeting


French drug major Sanofi (Euronext: SAN) has reported positive results from the GetGoal-F1 study with…

DiabetesLantusLyxumiaPharmaceuticalResearchSanofiZealand Pharma

Nycomed to market Norgine’s laxative MoviPrep in Russia and CIS


Swiss independent drugmaker Nycomed and Netherlands-headquartered Norgine, have entered into a licensing…

EuropeGastro-intestinalsLicensingMarkets & MarketingMoviPrepNorgineNycomedPharmaceutical

1 to 25 of 28 results

Back to top